

The Evolution of Medical Affairs: How Real-World Evidence (RWE) Transformed Drug Development and Market Access

Pranali P. Paradkar

Research Scholar, PhD., Maharashtra, India

Date of Submission: 20-05-2025

Date of Acceptance: 01-06-2025

ABSTRACT: The medical affairs landscape has undergone a significant transformation, with Real-World Evidence (RWE) playing a pivotal role in reshaping drug development and market access. This review explores the evolution of medical affairs from a traditional, supportive role to a strategic function driven by data, evidence, and value-based outcomes. By integrating RWE into clinical and commercial strategies, pharmaceutical companies now leverage insights from diverse sources, including electronic health records, registries, and patient-reported outcomes. The implications for regulatory decisions, payer negotiations, and clinical adoption are profound. This article provides a comprehensive overview of how RWE enhances decision-making, stakeholder engagement, and access to innovative therapies.

KEYWORDS: Medical Affairs, Real-World Evidence, RWE, Drug Development, Market Access, Value-Based Healthcare.

I. INTRODUCTION

Traditionally, medical affairs served a supportive function within the pharmaceutical industry, focusing on medical education, clinical trial support, and scientific communication. However, in the last decade, its role has evolved drastically. With growing emphasis on patient outcomes, health economics, and evidence-based value, Real-World Evidence (RWE) has emerged as a cornerstone of modern drug development and access strategy. This shift has positioned medical affairs at the intersection of clinical science, regulatory decision-making, and commercial success.

II. LITERATURE REVIEW

The integration of RWE into pharmaceutical operations has been extensively documented. Studies highlight the utility of RWE

in complementing randomized controlled trials (RCTs), especially for rare diseases, long-term safety evaluations, and outcomes in diverse populations. According to regulatory bodies like the FDA and EMA, RWE is increasingly considered in drug approvals, label expansions, and post-market surveillance. Evidence also supports the role of RWE in shaping payer perceptions by providing realistic projections of drug effectiveness and cost-efficiency in clinical practice.

III. DISCUSSION

The digital health revolution has enabled the collection and analysis of vast amounts of real-world data. Through collaborations with health systems, payers, and technology platforms, pharmaceutical companies use RWE to demonstrate treatment value. This evidence supports health technology assessments (HTAs) and enables outcome-based pricing models. Moreover, RWE facilitates precision medicine by identifying subgroups that benefit most from therapies. Despite its promise, challenges remain in data quality, standardization, and regulatory acceptance. Medical affairs teams play a critical role in navigating these challenges, ensuring ethical use of data, and maintaining scientific rigor.

IV. CONCLUSION

RWE has transformed the role of medical affairs from an operational support unit to a strategic driver of drug development and market access. As healthcare stakeholders demand more evidence of value, RWE offers a powerful tool to align innovation with outcomes that matter. Continued investment in data infrastructure, regulatory harmonization, and cross-functional collaboration will further solidify RWE's role in shaping the future of pharmaceutical innovation.

REFERENCES

- [1]. Rosenblatt, M.; Austin, CP.; Boutin, M.; Chin, WW.; Galson, SK.; Jain, SH.; McMurry-Heath, M.; Nussbaum, SR.; Orloff, J.; Weinberger, SE.; Woodcock, J., 2016, Innovation in Development, Regulatory Review, and Use of Clinical Advances, National Academy of Medicine, 1-16.
- [2]. A Hoos, A.; Anderson, J.; Boutin, M.; Dewulf, L.; Geissler, J.; Johnston, G.; Joos, A.; Metcalf, M.; Regnante, J.; Sargeant, I.; Schneider, RF.; Todaro, V.; Tougas, G., 2015, Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action, Therapeutic Innovation & Regulatory Science, 49(6), 929-939.
- [3]. Groves, P., 2013, The 'big data' revolution in healthcare: Accelerating value and innovation.
- [4]. Lezaun, J.; Montgomery, CM., 2015, The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development, Science, Technology, & Human Values, 40(1), 3-29.
- [5]. Brink, J.; Holmén, M., 2009, Capabilities and Radical Changes of the Business Models of New Bioscience Firms, Changing business models of new bioscience firms, 18(2), 109-120.
- [6]. Friedman, C.; Rubin, J.; Brown, J.; Buntin, M.; Corn, M.; Etheredge, L.; Gunter, C.; Musen, M.; Platt, R.; Stead, W.; Sullivan, K.; Van Houweling, D., 2015, Toward a science of learning systems: a research agenda for the high-functioning Learning Health System, J Am Med Inform Assoc, 43-50.
- [7]. Gardner, SP., 2005, Ontologies and semantic data integration, DDT, 10(14), 1001-7.
- [8]. Moran, M., 2000, Understanding the welfare state: the case of health care, British Journal of Politics and International Relations, 2(2), 135-160.
- [9]. Ross, MK.; Wei, W.; Ohno-Machado, L., 2014, "Big Data" and the Electronic Health Record, IMIA Yearbook of Medical Informatics, 97-104.
- [10]. Nipp, RD.; Kelly, MJ.; Williams, CD.; Kamal, AH., 2013, Evolution of the Quality Oncology Practice Initiative Supportive Care Quality Measures Portfolio and Conformance at a Veterans Affairs Medical Center, Journal of oncology practice, 9(3), e86-89.
- [11]. Doyle-Lindrud, S., 2015, The Evolution of the Electronic Health Record, Clinical Journal of Oncology Nursing, 19(2), 153-4.
- [12]. Richman, DD., Wrin, T.; Little, SJ.; Petropoulos, CJ., 2013, Rapid evolution of the neutralizing antibody response to HIV type 1 infection, PNAS, 100(7), 4144-4149.
- [13]. Sherman, RE., Anderson, SA.; Pan, GJ.; Grey, GW.; Gross, T.; Hunter, NL.; LaVange, L.; Marinac-Dabic, D.; Marks, PW.; Robb, MA.; Shuren, J.; Temple, R.; Woodcock, J.; Yue, LQ.; Califf, RM., 2016, Real-World Evidence — What Is It and What Can It Tell Us?, The new England journal of medicine, 2293-97.
- [14]. Eichler, HG.; Baird, LG.; Barker, R.; Bloechl-Daum, B.; Børllum-Kristensen, F.; Brown, J.; Chua, R.; Signore, SD.; Dugan, U.; Ferguson, J.; Garner, S.; Goettsch, W.; Haigh, J.; Honig, P.; Hoos, A.; Huckle, P.; Kondo, T.; Cam, YL.; Leufkens, H.; Lim, R.; Longson, C.; Lumpkin, M.; Maraganore, J.; O'Rourke, B.; Oye, K.; Pezalla, G.; Pignatti, F.; Raine, J.; Rasi, G.; Salmonson, T.; Samaha, D.; Schneeweiss, S.; Siviero, PD.; Skinner, M.; Teagarden, JR.; Tominaga, T.; Trusheim, MR.; Tunis, S.; Unger, TF.; Vamvakas, S.; Hirsch, s., 2015, From Adaptive Licensing to Adaptive Pathways: Delivering a Flexible Life-Span Approach to Bring New Drugs to Patients, State of the art, 97(3), 234-246.
- [15]. Gupta, SK.; Nayak, RP., 2013, An insight into the emerging role of regional medical advisor in the pharmaceutical industry, Perspectives in Clinical Research, 4(3), 186-190.
- [16]. Lexchin J., 1993, Interactions between physicians and the pharmaceutical industry: What does the literature say?, CAN MED ASSOC J, 149(10), 1401-07.
- [17]. Edwards, LD.; Fox, AW.; Stonier, PD., 2011, Principles and Practice of Pharmaceutical Medicine.
- [18]. Angell, M., 2004, Excess in the pharmaceutical industry, CMAJ, 171(12), 1451-53.
- [19]. Young, MD., 1990, Globalization of the Pharmaceutical Industry: The Physician's Role in Optimizing Drug Use, J Clin Pharmacol, 30, 990-993.
- [20]. Parsons, S.; Starling, B.; Mullan-Jensen, C.; Tham, S.; Warner, K.; Wever, K., 2016, What do pharmaceutical industry

- professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study, *BMJ Open*, 1-11.
- [21]. Lineberry, N.; Berlin, JA.; Mansi, B.; Glasser, S.; Berkwits, M.; Klem, C.; Bhattacharya, A.; Citrome, L.; Enck, R.; Fletcher, J.; Haller, D.; Chen, T.; Laine, C., 2016, Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective, *BMJ*, 1-11.
- [22]. Alam, T.; Shahi, M., 2012, Factors Affecting Job Satisfaction, Motivation and Turnover Rate of Medical Promotion Officer (MPO) in Pharmaceutical Industry: A Study Based in Khulna City, *Asian Business Review*, 1(1), 126-131.
- [23]. Kahn, M.; Gastrow, M., 2008, Pharmacologically active: clinical trials and the pharmaceutical industry, *SAMJ*, 98(2).
- [24]. Prabhu, VG., Pharmaceutical Industry in India, 47-49.
- [25]. Messis, C., 2001, Ethical Issues (Conflict of Interest) between the Medical Profession and the Pharmaceutical Industry, *Interventional Neuroradiology*, 191-192.